Format

Send to

Choose Destination
Nat Rev Clin Oncol. 2012 Sep;9(9):510-9. doi: 10.1038/nrclinonc.2012.111. Epub 2012 Jul 17.

T-cell therapy in the treatment of post-transplant lymphoproliferative disease.

Author information

1
Center for Cell and Gene Therapy, Department of Pediatrics, Baylor College of Medicine, The Methodist Hospital and Texas Children's Hospital, 1102 Bates Street, Houston, TX 77030, USA. cmbollar@txch.org

Abstract

Post-transplant lymphoproliferative diseases (PTLD) associated with Epstein-Barr virus (EBV) infection often develop after organ and haematopoietic stem-cell transplantation. These lymphoproliferative diseases are tumours that usually express all latent EBV viral proteins, and are therefore amenable to T-cell-based immune therapies, such as donor lymphocyte infusions and the adoptive transfer of EBV-specific cytotoxic T lymphocytes. In this Review, we describe current approaches of T-cell-based therapies to treat PTLD, and describe strategies that improve the feasibility of such treatment.

PMID:
22801669
PMCID:
PMC3743122
DOI:
10.1038/nrclinonc.2012.111
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Nature Publishing Group Icon for PubMed Central
Loading ...
Support Center